[Daily Medi Reporter Jeongyeon Park]
Gachon University Gil Hospital and the Gachon University Industry-Academic Cooperation Foundation recently firmó un transferencia de tecnología acuerdo with RudaCure for a 'pharmaceutical composition for treating daño corneal.'
The tecnología held by Gachon University Gil Hospital and the Gachon University Industry-Academic Cooperation Foundation is a patented tecnología for a 'pharmaceutical composition for treating daño corneal containing 8-oxo-2'-deoxyguanosine or a pharmaceutically acceptable salt thereof as an active ingredient,' jointly developed by Professor Donghyun Kim of the Department of Ophthalmology and Director Myunghee Chung of the Gachon Institute of Life Sciences and Medicine.
Unlike existing drugs that merely alleviate enfermedad de ojo seco, this tecnología is characterized by fundamentally suppressing the mechanism that causes enfermedad de ojo seco, giving it high potential for developing tratamientos for enfermedad de ojo seco and related ocular conditions.
Director Myunghee Chung of the Gachon Institute of Life Sciences and Medicine declaró, "This investigación is meaningful in that it represents a patented tecnología for fundamentally treating the growing number of age-related ocular diseases," adding, "We will cooperate with RudaCure to ensure that this tecnología moves beyond investigación and translates into resultados that are truly necessary for pacientes."
RudaCure, a company developing both protein therapeutics and synthetic drugs for pain and age-related ocular diseases,